CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+11.72%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$249M
AUM Growth
+$249M
(+4.7%)
Cap. Flow
+$8.57M
Cap. Flow
% of AUM
3.45%
Top 10 Holdings %
Top 10 Hldgs %
35.47%
Holding
513
New
48
Increased
267
Reduced
44
Closed
122
Top Buys
| 1 |
iQIYI
IQ
|
$12.8M |
| 2 |
Amazon
AMZN
|
$3.31M |
| 3 |
uniQure
QURE
|
$3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$2.97M |
| 5 |
DexCom
DXCM
|
$2.87M |
Top Sells
| 1 |
Novo Nordisk
NVO
|
$3.65M |
| 2 |
Tesla
TSLA
|
$3.64M |
| 3 |
Procter & Gamble
PG
|
$3.53M |
| 4 |
Nike
NKE
|
$3.17M |
| 5 |
CVS Health
CVS
|
$2.99M |
Sector Composition
| 1 | Technology | 35.23% |
| 2 | Healthcare | 25.2% |
| 3 | Consumer Discretionary | 20.47% |
| 4 | Communication Services | 8.05% |
| 5 | Financials | 3.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
Galapagos
GLPG
$2.05B
| $6.04K | ﹤0.01% |
136
+4
| +3% | +$178 |
|
277
89bio
ETNB
$1.36B
| $6.02K | ﹤0.01% |
473
+107
| +29% | +$1.36K |
|
278
Mersana Therapeutics
MRSN
$35.3M
| $5.94K | ﹤0.01% |
1,014
+104
| +11% | +$609 |
|
|
TVRD
279
Tvardi Therapeutics, Inc. Common Stock
TVRD
$267M
| $5.86K | ﹤0.01% |
546
+43
| +9% | +$462 |
|
280
Design Therapeutics
DSGN
$339M
| $5.83K | ﹤0.01% |
568
+45
| +9% | +$462 |
|
|
BLUE
281
DELISTED
bluebird bio
BLUE
| $5.83K | ﹤0.01% |
842
+120
| +17% | +$830 |
|
282
Edgewise Therapeutics
EWTX
$1.54B
| $5.74K | ﹤0.01% |
642
+175
| +37% | +$1.56K |
|
283
HilleVax
HLVX
$104M
| $5.67K | ﹤0.01% |
+339
| New | +$5.67K |
|
284
MaxCyte
MXCT
$144M
| $5.66K | ﹤0.01% |
1,037
+85
| +9% | +$464 |
|
285
HUTCHMED
HCM
$2.62B
| $5.54K | ﹤0.01% |
375
+16
| +4% | +$237 |
|
286
SIGA Technologies
SIGA
$608M
| $5.46K | ﹤0.01% |
742
+59
| +9% | +$434 |
|
|
CINC
287
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $5.46K | ﹤0.01% |
+444
| New | +$5.46K |
|
288
Protagonist Therapeutics
PTGX
$3.59B
| $5.46K | ﹤0.01% |
500
+40
| +9% | +$436 |
|
289
Ardelyx
ARDX
$1.56B
| $5.43K | ﹤0.01% |
+1,904
| New | +$5.43K |
|
|
CBAY
290
DELISTED
Cymabay Therapeutics
CBAY
| $5.39K | ﹤0.01% |
860
+67
| +8% | +$420 |
|
291
Erasca
ERAS
$391M
| $5.36K | ﹤0.01% |
1,243
+99
| +9% | +$427 |
|
292
Nurix Therapeutics
NRIX
$709M
| $5.26K | ﹤0.01% |
479
+39
| +9% | +$428 |
|
293
Kiniksa Pharmaceuticals
KNSA
$2.6B
| $5.26K | ﹤0.01% |
351
+28
| +9% | +$419 |
|
|
NIU
294
Niu Technologies
NIU
$340M
| $5.23K | ﹤0.01% |
+1,000
| New | +$5.23K |
|
295
Sangamo Therapeutics
SGMO
$160M
| $5.23K | ﹤0.01% |
1,665
+199
| +14% | +$625 |
|
|
ICPT
296
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $5.21K | ﹤0.01% |
421
+142
| +51% | +$1.76K |
|
|
IGMS
297
DELISTED
IGM Biosciences
IGMS
| $5.04K | ﹤0.01% |
296
+24
| +9% | +$408 |
|
|
AMRN
298
Amarin Corp
AMRN
$312M
| $4.93K | ﹤0.01% |
4,078
+375
| +10% | +$454 |
|
299
Cullinan Oncology
CGEM
$453M
| $4.91K | ﹤0.01% |
465
+38
| +9% | +$401 |
|
|
ABCM
300
DELISTED
Abcam plc American Depositary Shares
ABCM
| $4.9K | ﹤0.01% |
315
+73
| +30% | +$1.14K |
|